SOLU-CORTEF (hydrocortisone sodium succinate) by Pfizer is clinical pharmacology glucocorticoids, naturally occurring and synthetic, are adrenocortical steroids that are readily absorbed from the gastrointestinal tract. First approved in 1955.
Drug data last refreshed 2d ago
SOLU-CORTEF is a water-soluble, rapid-acting injectable glucocorticoid (hydrocortisone sodium succinate) that provides immediate anti-inflammatory and immunomodulatory effects. It is indicated for acute hematologic malignancies including Acute Myeloid Leukemia, Myelodysplastic Syndrome, and Juvenile Myelomonocytic Leukemia. The drug works by binding glucocorticoid receptors to suppress immune response and reduce inflammation, with demonstrable effects within one hour and near-complete excretion within 12 hours.
Product approaching loss of exclusivity with modest Part D utilization (9,502 claims); brand teams should anticipate shrinking headcount and transition to generic/commodity positioning.
CLINICAL PHARMACOLOGY Glucocorticoids, naturally occurring and synthetic, are adrenocortical steroids that are readily absorbed from the gastrointestinal tract. Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on SOLU-CORTEF at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moSOLU-CORTEF generates no dedicated brand-specific job openings (0 linked roles), reflecting its mature, generic-competitive status and limited commercial exclusivity. Career opportunities are constrained to small hospital/pharmacy teams, generic manufacturers, and cost/access roles rather than high-profile brand management or medical affairs positions.